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Background
HPV-associated ano-genital infections represent the most
common sexually-transmitted disease in the general
population. The incidence of HPV-associated cancers has
been increasing in HIV-infected patients. HPV vaccina-
tion may be an approach to reduce the risk of HPV-
associated cancers in HIV-infected patients and a
combined strategy of screening and vaccination may
guarantee an adequate prevention of HPV-associated
lesions. Immunogenicity of HPV vaccines in HIV-
infected patients is still not adequately evaluated. We
analyzed immunogenicity of a quadrivalent HPV vaccine
in HIV-infected patients without molecular evidence of
vaccine-type HPV infection focusing on HPV-specific
cell mediated immunity (CMI).
Methodology
31 ARV-treated HIV-infected adolescents (age range
28-14 years, with undetectable viremia and effective
CD4 recovery) and 25 sex- and age-matched HIV-sero-
negative healthy controls were enrolled in the study.
HPV-16/18/6/11 VLP vaccine (Gardasil®) was adminis-
tered 3 times (baseline, 2 and 6 months). Immune acti-
vation (CD4/CD25/HLADRII, CD8/CD25/HLADRII),




HIV-infected individuals showed: 1) no changes in CD4
counts, percentage of CD4 cells and HIV viral load; 2) a
significant increase in naїve CD8 T-cells, activated CD8
T-cells and in central memory CD4 and CD8 T-cells;
3) a significant reduction in terminally differentiated
CD8 T-cells; 4) a significant increase in unstimulated
and in HPV-specific IL2+/CD4+, IFN-g+/CD4+, IFN-g
+/CD8+ and TNF-a+/CD8+ T-cells; and 5) a significant
increase in HPV-specific Perforin- and Granzyme
B-secreting CD8 T-cells. Results obtained in HIV-
infected patients were comparable to those seen in HC.
Conclusions
HPV-16/18/6/11 VLP vaccine induces strong HPV-
specific cell-mediated immunity in ARV-treated HIV-
infected individuals that are comparable to those
observed in HIV-seronegative controls. HPV-specific
CMI is likely an important component of the protective
effect of this vaccine, data herein indicating that this
arm of immunity is not impaired in ARV-treated HIV
infected individuals.
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